Drug delivery systems for targeting the blood-brain barrier for the treatment of malignant brain tumor: Current status and prospects of drug delivery approaches with Pathological point

Abstract

Brain tumors are defined as primary intracranial tumors in the brain.  These tumors account for 1.8% of newly diagnosed cancers and 2.3% of cancer-related deaths worldwide.  The purpose of the present study is to investigate drug delivery systems to target the blood-brain barrier for the treatment of malignant brain tumors: current status and prospects of drug delivery approaches.

Materials and methods: This research was a clinical trial that was conducted in 1402 at the Imam Khomeini educational-therapeutic center in Tehran.  The statistical population of the study was made up of patients with brain malignancy who referred to the mentioned centers. The procedure was that after obtaining the approval of the medical ethics committee of Tehran University of Medical Sciences, 60 patients with brain cancer were selected and randomly assigned.  They were divided into two groups of 30 people. The first group underwent new treatments for malignancy according to the stage of disease progression.  The second group includes patients who used old treatment methods to treat malignancy.  Finally, the obtained data were analyzed using t-test, 2 Mann-Whitney and repeated measures ANOVA in SPSS software version 24 (version 24, IBM Corporation, Armonk, NY).

Conclusion: It is important to pay attention to the structural features of the blood-brain barrier and the way of intercellular transmission, as well as to choose the appropriate drug and drug delivery system for the targeted and systematic treatment of central nervous system diseases.  has been  Also, drug delivery systems based on nanoparticles and the most important nanocarrier structures including biopolymer nanoparticles, nanoliposomes, dendrimers and solid lipid nanoparticles have been investigated.